All In Biotech

Drug Trial Radar · NCT01135680

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

May 2010

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Arm 1: Primary Objective: • To determine the safety and tolerability of multiple ascending, supratherapeutic doses of HPN-100. Arm 2: Primary Objective: • To assess the effects of steady-state levels of HPN-100 metabolites (4 phenylbutyric acid \[PBA\], phenylacetic acid \[PAA\], and phenylacetylglutamine \[PAGN\]) on 12-lead electrocardiogram (ECG) parameters in healthy male and female subjects with the primary endpoint being the time-matched change from baseline in the QT interval corrected for heart rate (HR) based on an individual correction method (QTcI).

Conditions

  • Drug Toxicity

Interventions

  • HPN-100Drug

    single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days

  • HPN-100 or PlaceboDrug

    single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days

  • PlaceboDrug

    single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days

  • MoxifloxacinDrug

    single oral 400-mg dose on study Day 3

  • HPN-100Drug

    single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days

  • HPN-100Drug

    single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability as measured by the rate and severity of adverse events in each treatment group.Time frame: 3-day treatment period
  2. Changes from baseline QTcI as a measure of effects of study-state HPN-100 metabolites: PBA, PAA, and PAGNTime frame: 4 treatment regimens for 3 days with a 4 day minimum washout period between treatments

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Pharmacology, Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.